6505--Pluvicto and Lutathera | VA GLA

Active

Contract Opportunity

NOTICE OF INTENT TO SOLE SOURCE

This notice is being published in accordance with Federal Acquisition Regulation (FAR) Subpart 5.101 requiring dissemination of information for proposed contract actions. This is a notice of intent to award a sole source contract and is not a request for competitive quotes/proposals. The Department of Veterans Affairs, Network Contracting Office (NCO) 22, located at 4811 Airport Plaza Drive, Long Beach, CA is issuing this Notice of Intent (NOI) to inform industry contractors of the Government’s intent to execute a Sole Source Delivery Order under FAR Part 8, specifically FAR Part 8.405-6(a)(1)(B), Only One Available Source. The North American Industry Classification System (NAICS) for this requirement is 325412, Pharmaceutical Preparation Manufacturing. The Federal Supply Class (FSC) is 6505, Drugs and Biologicals. The Small Business Administration (SBA) size standard for this sector is 1,300 Employees.

The intended contractor is Novartis Pharmaceuticals Corporation located at 59 Route 10, East Handover, NJ 07936. Place of Performance is the VA Greater Los Angeles Healthcare System located at 11301 Wilshire Blvd, Los Angeles, CA 90073. VA Greater Los Angeles Nuclear Medicine Service intends to purchase PLUVICTO LUTETIUM LU 177 VIPIVOTIDE TETRA 27mCi/ML and LUTATHERA LUTETIUM LU 177 DOTATATE in quantities listed below:

NDC#

Contract

Description

Qty

UOM

69488-0010-61

36F79720D0180

PLUVICTO LUTETIUM LU 177 VIPIVOTIDE TETRA 27mCi/ML

105

EA

69488-0003-01

36F79720D0180

LUTATHERA LUTETIUM LU 177 DOTATATE

10

EA

VA Greater Los Angele Healthcare System Nuclear Medicine Service requires Pluvicto to treat advance prostate cancer and Lutathera to treat neuroendocrine tumor therapy. Radiopharmaceuticals requested were awarded to Novartis Pharmaceuticals Corporations on 7/30/2020 under contract 36F79720D0180.

This notice of intent is neither a formal solicitation nor a request for competitive proposals. No solicitation document is available and telephone requests will not be honored. No award will be made on the basis of unsolicited quotations or offers received in response to this notice. Any response to this notice must show clear and compelling evidence that the responding company can provide the same items/services, and that competition will be advantageous to the Government. The intent of this synopsis is for informational purposes only. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement. A determination by the Government not to compete this action based on this notice is solely within the discretion of the Government.

All inquiries and concerns must be addressed in writing via e-mail to Hestia Sim, Hestia.Sim@va.gov with RESPONSE TO INTENT TO SOLE SOURCE Pluvicto and Lutathera in the subject line. All interested parties who are responsible, certified, and capable may identify their interest and may submit a capabilities statement no later than 10:00 AM Pacific Local Time August 15, 2025, to the above-mentioned point of contact. The interested parties bear full responsibility to ensure complete transmission and timely receipt. The Department of Veterans Affairs will NOT be responsible for any costs incurred by interested parties in responding to this notice of intent.

Attachments/Links